Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 750
Single User License Price INR 50588
Corporate User License Price USD 2250
Corporate User License Price INR 151763
Site License Price USD 1500
Site License Price INR 101175
Request a Quote

Report Title

Cesca Therapeutics Inc. (KOOL)-Product Pipeline Analysis, 2016 Update

Quote Request for License Type
License Type Price  
Single User License USD 750
Site License USD 1500
Enterprise Wide License USD 2250
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Cesca Therapeutics Inc. (KOOL)-Product Pipeline Analysis, 2016 Update


Quote Request for License Type
License Type Price  
Single User License USD 750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Cesca Therapeutics Inc. (KOOL)-Product Pipeline Analysis, 2016 Update

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Cesca Therapeutics Inc. (KOOL)-Product Pipeline Analysis, 2016 Update



Executive Summary

Summary

Cesca Therapeutics Inc. (Cesca) formerly ThermoGenesis Corp. is a medical equipment company. It researches, develops, and commercializes cell based therapeutics for application in regenerative medicine. Its lead technology platform, SurgWerks is used for the collection, separation, storage and delivery of stem cells from adult tissue sources including cord blood and bone marrow. The company's CellWerks MXP system is an integrated protocol and equipment with disposables for rapid intra-laboratory use under the direction of a licensed physician. It finds application in bone marrow transplantation and cellular purification from cord blood. It also offers AutoXpress and MarrowXpress devices for isolating and concentrating hematopoietic stem cells from cord blood and bone marrow; BioArchive automated cryogenic device and manual bag sets for use in the processing and cryogenic storage of cord blood. The company markets its products to patients, physician and partners in three target markets, namely, cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. Cesca is headquartered in Rancho Cordova, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Cesca Therapeutics Inc.

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio,

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Cesca Therapeutics Inc. Company Overview 6

Cesca Therapeutics Inc. Company Snapshot 6

Cesca Therapeutics Inc. Pipeline Products and Clinical Trials Overview 7

Cesca Therapeutics Inc.-Pipeline Analysis Overview 8

Business Description 8

Key Facts 9

Cesca Therapeutics Inc.-Major Products and Services 10

Cesca Therapeutics Inc. Clinical Trials by Trial Status 11

Cesca Therapeutics Inc. Pipeline Products Overview 13

CellWerks-ABO Mismatch 13

CellWerks-ABO Mismatch Product Overview 13

CellWerks-Haplo-identical 14

CellWerks-Haplo-identical Product Overview 14

CellWerks BMT 15

CellWerks BMT Product Overview 15

SurgWerks-AVN 16

SurgWerks-AVN Product Overview 16

SurgWerks-Ischemic Stroke 17

SurgWerks-Ischemic Stroke Product Overview 17

SurgWerks-Non-Healing Ulcers 18

SurgWerks-Non-Healing Ulcers Product Overview 18

SurgWerks-Non-Union Fractures 19

SurgWerks-Non-Union Fractures Product Overview 19

SurgWerks-Osteoarthritis 20

SurgWerks-Osteoarthritis Product Overview 20

SurgWerks-SF 21

SurgWerks-SF Product Overview 21

SurgWerks AMI Kit 22

SurgWerks AMI Kit Product Overview 22

SurgWerks AMI Kit Clinical Trial 23

SURGWERKS-CLI Therapy Kit-Intra-arterial 24

SURGWERKS-CLI Therapy Kit-Intra-arterial Product Overview 24

SURGWERKS-CLI Therapy Kit-Intra-arterial Clinical Trial 25

VXP System 26

VXP System Product Overview 26

VXP System Clinical Trial 27

Cesca Therapeutics Inc.-Key Competitors 28

Cesca Therapeutics Inc.-Key Employees 29

Cesca Therapeutics Inc.-Key Employee Biographies 30

Cesca Therapeutics Inc.-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Cesca Therapeutics Inc., Recent Developments 32

Sep 20, 2016: Cesca Therapeutics Reports Fourth Quarter and Fiscal 2016 Year End Results 32

Sep 19, 2016: Cesca Granted Patents for technology Fundamental Proprietary SurgWerks Platform for CLI 33

Sep 19, 2016: Cesca Granted Patents for Technology Fundamental Proprietary SurgWerks Platform for AMI 33

Aug 03, 2016: Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study 34

Aug 02, 2016: Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture 34

Aug 01, 2016: Cesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for SurgWerks CLI Pivotal Trial 34

Jun 20, 2016: Cesca Therapeutics Appoints Mark Bagnall to Its Board of Directors 35

Jun 01, 2016: Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks CLI Pivotal Trial 35

May 24, 2016: Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting 36

May 20, 2016: Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Cesca Therapeutics Inc. Clinical Trials by Trial Status 11

List of Tables

Cesca Therapeutics Inc. Pipeline Products and Clinical Trials Overview 7

Cesca Therapeutics Inc. Pipeline Products by Indication 7

Cesca Therapeutics Inc. Clinical Trials by Trial Status 7

Cesca Therapeutics Inc., Key Facts 9

Cesca Therapeutics Inc., Major Products and Services 10

Cesca Therapeutics Inc. Clinical Trials by Trial Status 11

Cesca Therapeutics Inc. Clinical Trials Summary 12

CellWerks-ABO Mismatch-Product Status 13

CellWerks-ABO Mismatch-Product Description 13

CellWerks-Haplo-identical-Product Status 14

CellWerks-Haplo-identical-Product Description 14

CellWerks BMT-Product Status 15

CellWerks BMT-Product Description 15

SurgWerks-AVN-Product Status 16

SurgWerks-AVN-Product Description 16

SurgWerks-Ischemic Stroke-Product Status 17

SurgWerks-Ischemic Stroke-Product Description 17

SurgWerks-Non-Healing Ulcers-Product Status 18

SurgWerks-Non-Healing Ulcers-Product Description 18

SurgWerks-Non-Union Fractures-Product Status 19

SurgWerks-Non-Union Fractures-Product Description 19

SurgWerks-Osteoarthritis-Product Status 20

SurgWerks-Osteoarthritis-Product Description 20

SurgWerks-SF-Product Status 21

SurgWerks-SF-Product Description 21

SurgWerks AMI Kit-Product Status 22

SurgWerks AMI Kit-Product Description 22

SurgWerks AMI Kit-Assessment of Safety of SurgWerks-AMI and VXP System for ST- Elevated Myocardial Infarction (STEMI) Caused Left Ventricle Ejection Fraction (LVEF) and Acute Myocardial Infarction (AMI) 23

SURGWERKS-CLI Therapy Kit-Intra-arterial-Product Status 24

SURGWERKS-CLI Therapy Kit-Intra-arterial-Product Description 24

SURGWERKS-CLI Therapy Kit-Intra-arterial-Safety and Effectiveness of the SurgWerks-CLI Kit and VXP System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-reconstructable Critical Limb Ischemia Patients 25

VXP System-Product Status 26

VXP System-Product Description 26

VXP System-Assessment of Safety of SurgWerks-AMI and VXP System for ST- Elevated Myocardial Infarction (STEMI) Caused Left Ventricle Ejection Fraction (LVEF) and Acute Myocardial Infarction (AMI) 27

VXP System-Safety and Effectiveness of the SurgWerks-CLI Kit and VXP System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-reconstructable Critical Limb Ischemia Patients 27

Cesca Therapeutics Inc., Key Employees 29

Cesca Therapeutics Inc., Key Employee Biographies 30

Table 1: Cesca Therapeutics Inc., Other Locations 31

Cesca Therapeutics Inc., Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Cesca Therapeutics Inc., Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand